VolitionRx Participates in Launch of DETECSEPS Program in France
VolitionRx’s Nu.Q NETs H3.1 becomes the sole biomarker in a €6.3 million French program evaluating real-world early detection of sepsis.
Rhea-AI Summary
VolitionRx (VNRX) has joined the French government-funded €6.3 million (~$7.3 million) DETECSEPS consortium, where its Nu.Q® NETs H3.1 assay has been selected as the sole biomarker for real-world early detection of sepsis in France.
DETECSEPS, led by IHU SEPSIS and coordinated by AP-HP with HCL and industrial partner IDS France, will combine a routinely used clinical score with Volition’s biomarker to quantify sepsis risk on emergency department arrival and guide care within the first 24 hours. IDS France will supply the IDS i10® automated analyzer, which can deliver H3.1 results within about one hour. Sepsis is estimated to cause 21 million deaths globally and around 57,000 deaths annually in France. Volition estimates that, with approximately 166 million sepsis cases per year, the associated testing opportunity represents a multi-billion dollar total addressable market.
Positive
- €6.3 million French government-funded DETECSEPS program selects Nu.Q® NETs as sole biomarker
- Program targets real-world early sepsis detection in emergency departments across France
- IDS i10® analyzer can return H3.1 results within about one hour
- Volition cites ~166 million annual sepsis cases, implying multi-billion dollar testing TAM
Negative
- None.
Details
Market Reaction – VNRX
Following this news, VNRX has declined 0.29%, reflecting a mild negative market reaction. Our momentum scanner has triggered 44 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.27. Trading volume is exceptionally heavy at 159.8x the average, suggesting significant selling pressure.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Consortium funding
- €6.3 million (~$7.3 million)
- French government-funded DETECSEPS program
- Test result availability
- Within one hour
- H3.1 measurement using the IDS i10 automated analyzer
- Evaluation window
- First 24 hours
- Early sepsis risk assessment in emergency facilities
Historical Context
-
DETECSEPS was expected to begin recruitment after Nu.Q NETs sepsis validation
-
Nu.Q NETs H3.1 independently predicted mortality and renal replacement therapy
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
epigenetics medical
biomarker medical
national early warning score (news) 2 medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
French Government-Funded
DETECSEPS is an initiative of IHU SEPSIS – the world's first medical research center dedicated entirely to fighting sepsis, coordinated and sponsored by the Assistance Publique - Hôpitaux de
Professor Djillali Annane, Director of the IHU Sepsis and Head of the Intensive Care Medicine Department at the Raymond-Poincaré Hospital AP-HP commented:
"The day after World Sepsis Day, the launch of DETECSEPS marks a major milestone and, to our knowledge, a world first in the management of sepsis.
"Our ambition is to identify on arrival at the Emergency Department which patients with suspected infection are at risk of developing sepsis and require hospital care and which patients can be safely redirected home.
"By enabling earlier and fairer referral, DETECSEPS can transform the journey of each patient, improve the fluidity of emergency services and, beyond the hospital, reduce the socio-economic and environmental impact of sepsis.
"This is precisely the mission of the IHU SEPSIS: to transform research advances into concrete solutions to detect earlier, treat faster and save more lives."
Dr Andrew Retter, Medical Consultant, Volition, added:
"H3.1 levels can be routinely measured using the IDS i10® automated analyzer, provided by IDS France, with results available within one hour. The addition of the value of our biomarker could potentially enhance the application and reliability of National Early Warning Score (NEWS) 2 to triage the sickest patients. In my opinion, I believe this is both a huge and realistic expectation.
"DETECSEPS aligns with Volition's core purpose of operationalizing our understanding of epigenetics and in particular, of H3.1 in clinical practice, to help identify and monitor the severity of disease. The DETECSEPS program provides an opportunity to receive personalized care, adjusted to the risk of deterioration and progression to sepsis."
Sepsis is a dysregulated response of the body to an infection, responsible for the failure of one or more organs and which can quickly become life-threatening. Worldwide, this pathology is estimated to be responsible for 21 million deaths per year1. Rapid detection is therefore crucial to improve care and reduce mortality.
Professor Sébastien Beaune, Emergency Department, IHU SEPSIS, Ambroise Paré Hospital (AP-HP) and Coordinating Investigator of DECTECSEPS program commented:
"The DETECSEPS project aims to detect sepsis early in emergency facilities.
"It is estimated that sepsis is responsible for nearly 57,000 deaths per year in
"This project will evaluate an early detection device, based on the combination of a clinical score used routinely and a specific blood biomarker, Nu.Q® NETs H3.1, in order to quantify the risk of progression to sepsis, and quickly to initiate appropriate measures and treatments and therefore optimize the patient's journey in the first 24 hours."
Mr. Remi Rabeuf, VP Corporate Alliances and Strategic Partnership, Volition concluded:
"We are proud to be, alongside IDS France, industry members of this Consortium and are delighted that the program has been launched.
"We hope that through the earlier identification of sepsis lives can be saved, the quality of life of survivors can be improved and importantly that the burden on healthcare systems can be reduced.
"Sepsis carries a heavy social, economic and health burden worldwide. We believe this program could be rolled out not only nationally in
- Gray, Authia P et al. Global, regional, and national sepsis incidence and mortality, 1990–2021: a systemic analysis. The Lancet Global Health, 2025; 13(12): e2013-e2026. doi: 10.1016/s2214-109x(25)00356-0
- European Sepsis Report (accessed Sept 16th 2026)
About the Consortium
Initiated by the IHU Sepsis, led by Prof. Djillali Annane of the Raymond-Poincaré Hospital AP-HP, DETECSEPS brings together within the same consortium the AP-HP, the project's coordinating institution and sponsor of the clinical trials, the Hospices Civils de
For this project, the AP-HP is mobilizing several care services and research teams contributing to the management of sepsis. The DETECSEPS project will more specifically mobilize the emergency departments of the Bichat-Claude-Bernard and Ambroise Paré AP-HP hospitals, as well as the reference medical biology laboratories of these two sites, which contribute to the National Reference Centers (CNR) in the fight against infectious diseases. The AP-HP also provides methodological support and biostatistical analysis for the project (Department of Biostatistics of the Saint-Louis Hospital AP-HP, URC Saint Louis), medico-economic (URCEco, Hôtel-Dieu AP-HP) and public health (Public Health Department of the Raymond-Poincaré Hospital AP-HP).
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition is providing the Nu.Q® H3.1 Assay pro-bono to enable this important evaluation.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition's failure to achieve healthcare system or insurance plan reimbursement for its products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nu.Q®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
View original content to download multimedia:https://www.prnewswire.com/news-releases/volitionrx-participates-in-launch-of-detecseps-program-in-france-302881882.html
SOURCE VolitionRx Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What is the main objective of the DETECSEPS program in France?
The DETECSEPS program aims to detect sepsis early in emergency facilities by identifying, on arrival, which patients with suspected infection are at risk of developing sepsis and require hospital care and which can be safely redirected home. The project evaluates an early detection device based on combining a routinely used clinical score with the Nu.Q® NETs H3.1 blood biomarker to quantify the risk of progression to sepsis and quickly initiate appropriate measures and treatments in the first 24 hours.
Who are the main partners involved in the DETECSEPS consortium?
DETECSEPS is an initiative of IHU SEPSIS, coordinated and sponsored by Assistance Publique - Hôpitaux de Paris (AP-HP), in partnership with Hospices Civils de Lyon (HCL) and industrial partners IDS France and Volition. IDS France, part of Revvity, provides the IDS i10® automated analyzer, while Volition provides the Nu.Q® NETs biomarker.
How severe is the sepsis burden that DETECSEPS is targeting?
Sepsis is described as a dysregulated response to infection that can rapidly lead to organ failure and become life-threatening. It is estimated to be responsible for 21 million deaths per year worldwide and nearly 57,000 deaths per year in France. Survivors often experience significant ongoing health problems, underscoring the need for earlier detection and intervention.